6533b83afe1ef96bd12a6f0d
RESEARCH PRODUCT
Synergistic effect of recombinant CD4-immunoglobulin in combination with azidothymidine, dideoxyinosine and 0.5 beta-monoclonal antibody on human immunodeficiency virus infection in vitro.
T. KunisadaH. UshijimaT. KitamuraWerner E.g. Müllersubject
Combination therapymedicine.drug_classmedicine.medical_treatmentHIV InfectionsBiologyMonoclonal antibodyApplied Microbiology and BiotechnologyVirusZidovudinemedicineHumansLymphocytesCells Culturedvirus diseasesAntibodies MonoclonalDrug SynergismImmunotherapyVirologyIn vitroAnti-Bacterial AgentsDidanosinebiology.proteinDrug Therapy CombinationAntibodyNucleosideZidovudineCD4 Immunoadhesinsmedicine.drugdescription
Data are presented which indicate that combinations of rCD4 immunoglobulin with azidothymidine, dideoxyinosine or 0.5 beta mouse monoclonal antibodies directed against the V3 region of HIV-1, were more effective in treatment of acute HIV infection in vitro than each compound alone. It is suggested that combination therapy with these compounds is more beneficial in treatment of HIV-infected patients than monotherapy, especially with respect to a reduction of the known side effects and the formation of resistant HIV strains after treatment with nucleoside analogues.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1994-07-01 | Letters in applied microbiology |